GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.
TableEdit
PMID:16489009
You don't have sufficient rights on this wiki to edit tables. Perhaps you need to log in. Changes you make in the Table editor will not be saved back to the wiki
See Help for Help on this wiki. See the documentation for how to use the table editor
| Citation |
Dixelius, J, Olsson, AK, Thulin, A, Lee, C, Johansson, I and Claesson-Welsh, L (2006) Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein. Cancer Res. 66:2089-97 |
|---|---|
| Abstract |
Histidine-rich glycoprotein (HRGP) is an abundant heparin-binding plasma protein that efficiently arrests growth and vascularization of mouse tumor models. We have shown that the antiangiogenic effect of HRGP is dependent on its histidine/proline-rich domain, which needs to be released from the mother protein to exert its effects. Here we identify a 35-amino-acid peptide, HRGP330, derived from the histidine/proline-rich domain as endowed with antiangiogenic properties in vitro and in vivo. The mechanism of action of HRGP330 involves subversion of focal adhesion function by disruption of integrin-linked kinase (ILK) and focal adhesion kinase (FAK) functions, inhibition of vascular endothelial growth factor (VEGF)-induced tyrosine phosphorylation of the FAK substrate alpha-actinin, and, as a consequence, an arrest in endothelial cell motility. The disturbed focal adhesion function is reflected in the ability of HRGP as well as of HRGP330 to prevent endothelial cell adhesion to vitronectin in a manner involving alpha(v)beta3 integrin. In conclusion, HRGP330, which we define as the minimal antiangiogenic domain of HRGP, exerts its effects through signal transduction targeting focal adhesions, thereby interrupting VEGF-induced endothelial cell motility. |
| Links |
PubMed Online version:10.1158/0008-5472.CAN-05-2217 |
| Keywords |
Actinin/metabolism; Amino Acid Sequence; Animals; Cattle; Cell Movement/drug effects; Cell Movement/physiology; Endothelial Cells/cytology; Endothelial Cells/drug effects; Focal Adhesion Protein-Tyrosine Kinases/metabolism; Integrin alphaVbeta3/metabolism; Molecular Sequence Data; Neovascularization, Physiologic/drug effects; Paxillin/antagonists & inhibitors; Paxillin/biosynthesis; Peptide Fragments/chemistry; Peptide Fragments/pharmacology; Phosphorylation/drug effects; Protein Structure, Tertiary; Protein-Serine-Threonine Kinases/metabolism; Proteins/chemistry; Proteins/pharmacology; Vascular Endothelial Growth Factor A/antagonists & inhibitors; Vascular Endothelial Growth Factor A/metabolism; Vascular Endothelial Growth Factor A/pharmacology; Vascular Endothelial Growth Factor Receptor-2/metabolism |
| public |
| Cancel |
